The surveillance, epidemiology, and end results (SEER) program and pathology: Toward strengthening the critical relationship

American Journal of Surgical Pathology

Volumn 40, Issue 12, 2016, Pages e94-e102

  Duggan, Máire A ^a   Anderson, William F ^b   Altekruse, Sean ^c   Penberthy, Lynne ^c   Sherman, Mark E ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b Bethesda   (United States)

^c Cancer Control and Population Sciences   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

End Results program; Epidemiology; Pathology; SEER; Surveillance

Indexed keywords

TUMOR MARKER;

CANCER REGISTRY; GENETICS; HUMAN; INTERDISCIPLINARY COMMUNICATION; METABOLISM; MOLECULAR PATHOLOGY; NEOPLASMS; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; UNITED STATES;

BIOMARKERS, TUMOR; HUMANS; INTERDISCIPLINARY COMMUNICATION; MEDICAL ONCOLOGY; NEOPLASMS; PATHOLOGY, CLINICAL; PATHOLOGY, MOLECULAR; SEER PROGRAM; UNITED STATES;

EID: 84995804462     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000749     Document Type: Article

References (40)

1. Horlings HM, Flanagan AM, Huntsman DG. Categorization of cancer through genomic complexity could guide research and management strategies. J Pathol. 2015;236:397-402.
2. Alexander CB. Pathology graduate medical education (overview from 2006-2010). Hum Pathol. 2011;42:763-769.
3. Nakhleh RE. Core components of a comprehensive quality assurance program in anatomic pathology. Adv Anat Pathol. 2009;16:418-423.
4. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasm. Blood. 2016;127:2375-2390.
5. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer and the Association for Molecular Pathology. J Mol Diagn. 2013;15:416-453.
6. Hall KN, Kothari RU. Research fundamentals: IV. Choosing a research design. Acad Emerg Med. 1999;6:67-74.
7. Jordan S, Watkins A, Storey M, et al. Volunteer bias in recruitment, retention, and blood sample donation in a randomised controlled trial involving mothers and their children at six months and two years: a longitudinal analysis. PLoS One. 2013;8:1-17.
8. Park HS, Lloyd S, Decker RH, et al. Overview of the Surveillance, Epidemiology, and End Results database: evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36:183-190.
9. Altekruse SF, Rosenfeld GE, Carrick DM, et al. SEER cancer registry biospecimen research: yesterday and tomorrow. Cancer Epidemiol Biomarkers Prev. 2014;23:2681-2687.
10. Srigley JR, McGowan T, Maclean A, et al. Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol. 2009;99:517-524.
11. Yu JB, Gross CP, Wilson LD, et al. SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23:288-295.
12. Horne HN, Beena Devi CR, Sung H, et al. Greater absolute risk for all subtypes of breast cancer in the US than Malaysia. Breast Cancer Res Treat. 2015;149:285-291.
13. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106:1-8.
14. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protruberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007;56:968-973.
15. Lau CS, Mahendraraj K, Chamberlain RS. Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973-2010). Cancer Manag Res. 2015;7:301-309.
16. Menashe I, Anderson WF, Jatoi I, et al. Underlying causes of the black-white racial disparity in breast cancer mortality: a population based analysis. J Natl Cancer Inst. 2009;101:993-1000.
17. Albain KS, Unger JM, Crowley JJ, et al. Racial disparities in cancer survival among randomized clinical trials patients in the Southwest Oncology Group. J Natl Cancer Inst. 2009;101:984-992.
18. Rosenberg PS, Menashe I, Jatoi I, et al. Re: Racial disparities in cancer survival among randomized clinical trials patients in the Southwest Oncology Group. J Natl Cancer Inst. 2010;102:277.
19. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670-1674.
20. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone replacement therapy. J Natl Cancer Inst. 2011;103:296-305.
21. Elmore JG, Etzioni R. Effect of screening mammography on cancer incidence and mortality. JAMA Intern Med. 2015;175: 1490-1491.
22. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81: 1879-1886.
23. Schonfeld SJ, Pee D, Greenlee RT, et al. Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol. 2010;28:2411-2417.
24. Gentles AJ, Bratman SV, Lee LJ, et al. Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2015;107:1-11.
25. Thirunavukarasu P, Talati C, Munjal S, et al. Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. JAMA Surg. 2015;150:747-755.
26. Dinh KT, Mahal BA, Ziehr DR, et al. Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol. 2015;194:343-349.
27. Wang MJ, Ping J, Li Y, et al. Prognostic significance and molecular features of colorectal mucinous adenocarcinomas: a strobecompliant study. Medicine (Baltimore). 2015;94:1-8.
28. Dinan MA, Mi X, Reed SD, et al. Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among medicare beneficiaries with early-stage breast cancer, 2005-2009. JAMA Oncol. 2015;1:1098-1109.
29. Chamie K, Williams SB, Hershman DL, et al. Population-based assessment of determining predictors for quality of prostate cancer surveillance. Cancer. 2015;121:4150-4157.
30. Wong SM, Freedman RA, Sagara Y, et al. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer. 2015;121:4333-4340.
31. Rose BS, Jiang W, Punglia RS. Effect of lymph node metastasis size on breast cancer-specific and overall survival in women with node-positive breast cancer. Breast Cancer Res Treat. 2015;152: 209-216.
32. Park HS, Lloyd S, Decker RH, et al. Limitations and biases of the Surveillance, Epidemiology, and End Results Database. Curr Probl Cancer. 2012;36:216-224.
33. Sun M, Trinh QD. A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities. BJU Int. 2016;117:551-5522.
34. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J. 2001;7:251-258.
35. Shuch B, Hofmann JN, Merino MJ, et al. Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results Program. Urol Oncol. 2014;32:1-13.
36. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the Surveillance Epidemiology, and End Results registry versus independent review. J Natl Cancer Inst. 2004;96: 1105-1107.
37. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin Disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates. Cancer. 2001;92:218-224.
38. Matsuno RK, Sherman ME, Visvanathan K, et al. Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology and end results residual tissue repository. Cancer Causes Control. 2013;24:749-757.
39. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 2012;21:1031-1037.
40. Rositch AF, Nowak RG, Gravitt PE. Increased age and racespecific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014;120:2032-2038.